2 recruiting. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow GNT0003: new trials by email Literature Review of GNT0003 trials Research Report on GNT0003
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome Imlifidase, GNT0003 - Crigler-Najjar Syndrome | Phase 2 | Recruiting | Genethon | 3 | 2024-11-08 | 2024-12-03 |
| Gene Therapy for Severe Crigler Najjar Syndrome GNT0003 - Crigler-Najjar Syndrome | Not applicable | Recruiting | Genethon | 17 | 2018-03-19 | 2023-03-28 |
Genethon (2)
France (2) · Italy (1) · Netherlands (1)